News & Insights
Press & News
Company announcements and news from our partners.
MAPLE trial endpoint: PhenoBiome prebiotic raises gut microbial diversity, measured on Perseus Biomics’ DynaMAP platform
PALM SPRINGS, CA, UNITED STATES, September 29, 2026 / EINPresswire.com / — PhenoBiome today reported results from its MAPLE clinical trial, an eight-week study of a personalized nutritional (prebiotic) supplement in adults, run in collaboration with Perseus Biomics using the DynaMAP microbiome-profiling platform. The trial met its primary microbiome endpoint: species-level Shannon diversity rose by 0.55 points (from 4.91 to 5.46; p = 0.010) across the twelve completers, with eight of twelve gaining diversity against their own baseline.University of Roehampton celebrates national recognition for innovative addiction recovery projects
Dr Adele Costabile (School of Health and Life Sciences) with Back to Balance Test This research will validate a gut microbiome-based digital intervention that supports alcohol addiction recovery by improving gut health, mental wellbeing, and resilience against relapse.PhenoBiome Welcomes New Leadership and Validates Breakthrough Microbiome Modulation
PALM SPRINGS, CA, UNITED STATES, March 25, 2025 /EINPresswire.com / PhenoBiome, Inc., a pioneering leader in personalized microbiome solutions, today announced the appointment of Brian Russon as Chief Executive Officer (CEO) and Kait Mikes as Chief Operating Officer (COO).PhenoBiome launches human gut microbiome assay with Genetic Direction
SAN FRANCISCO, Sept. 23, 2021 /PRNewswire/ — PhenoBiome today announced it will launch its first human gut microbiome assay through Genetic Direction, a Dallas-based distributor of genetics-based health management programs. Clinical Enterprise, Inc., a Eurofins Scientific company, will process the assays in its CLIA- and CAP-certified laboratory.
Key Papers
Selected papers describing PhenoBiome’s technology and its application to the human gut microbiome.
Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity
Read paper ↗Human milk oligosaccharide metabolism and antibiotic resistance in early gut colonizers: insights from bifidobacteria and lactobacilli in the maternal-infant microbiome
Read paper ↗Mechanistic insights into microbiome-dependent and personalized responses to dietary fibre in a randomized controlled trial
Read paper ↗Integrative genomic reconstruction reveals heterogeneity in carbohydrate utilization across human gut bifidobacteria
Read paper ↗In vivo manipulation of human gut Bacteroides fitness and carbohydrate utilization machinery by abiotic oligosaccharides
Read paper ↗Prevotella copri and microbiota members mediate the beneficial effects of a therapeutic food for malnutrition
Read paper ↗Bioactive glycans in a microbiome-directed food for children with malnutrition
Read paper ↗Evaluating microbiome-directed fibre snacks in gnotobiotic mice and humans
Read paper ↗Micronutrient Requirements and Sharing Capabilities of the Human Gut Microbiome
Read paper ↗Extended Publications
Publications on PhenoBiome’s technology and its applications, listed newest first.
Publication legend
D Methodology — Development or description of computational methods, including genomics-based reconstruction of metabolic pathways and regulatory mechanisms.
A Application — Use of the methodology to address a biological or medical problem.
V Experimental validation — Experimental testing of bioinformatics-based predictions.
Where shown, letter badges retain the original publication classifications.
